NR1H4 and metabolic dysfunction-associated steatotic liver disease: As demonstrated by Yang et al. [103], Ginsenoside Rh4 may exert an interventional effect on non-alcoholic fatty liver disease (NAFLD) by regulating bile acid metabolism, lipid metabolism, and the phenotypes of hepatic inflammatory factors in the liver and intestine through the farnesoid X receptor (FXR) signaling pathway.